Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas

Mischler, Nicholas E., M.D.; Turmey, Douglass C., M.D., Ph.D.; Klaz, Jerry, Ph.D.; Borden, E. C., M.D.; Ramirez, C., M.D.; Banerjee, T. K., M.D; Carr, R. M., M.D.; Zaentz, S. D., M.D.; Graf, Jane, B.A.

American Journal of Clinical Oncology: January 1981 - Volume 4 - Issue 4 - p 407–410

IN A PHASE II STUDY dibromoduleitol (DBD), an alpha-omega dibrominated hexitol, was used to treat 99 previous treated patients with colon. rectal. kidney. and other tumors Six patients were ineligible and 10 patients were nonevaluable for response. Aside from thrombo-eytopenia toxicity was moderate. Twenty-there patients had platelet nadirs of less than 50,000/mm3 and there were three thromboeytopenie-associated drug deaths. One of 21 rectal and 1 of 13 kidney cancer patients entered a remission. All but seven patients had received previous treatment with one or mure cytotoxic agents. previous treated patients with colorectal and kidney cancer appear to be resistant to DBD.

Wisconsin Clinical Cancer Center, Department of Human Oncology, Madison, Wisconsin.

© Lippincott-Raven Publishers.